Jump to content

New Workflow System for the Design, Production, and Analytics of Antibody Drug Conjugates (ADCs)

Antibody Engineering & Therapeutics, San Diego, CA, USA
May 8, 2020

Antibody Drug Conjugates (ADCs), or immunoconjugates, play an increasingly important role as a new class of oncology medicines which use the selectivity of monoclonal antibodies to achieve targeted delivery of cytotoxic drugs. However, the underlying ADC discovery and development process is complex and poses significant challenges in that systematic ADC design uses a combination of optimal conjugation strategy (e.g. lysines, cysteines, Fc glycans, non-natural amino acids), linkers (e.g. cleavable, non-cleavable), and small-molecule toxophores (e.g. MMAE, DM1, Calicheamicin). Here, we present Genedata Biologics™, an enterprise workflow platform that supports the full ADC discovery process from antibody screening and engineering, to antibody expression, purification, drug conjugation and reporting of ADC-specific analytics (e.g. DAR, drug distribution, homogeneity). The platform enables the registration and tracking of large panels of ADC candidates, and incorporates results from analytics and functional assays in one integrated system, thereby substantially increasing throughput and efficiency of the ADC discovery process.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy